Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) Wednesday reported a narrower net loss for the third quarter of 2025. Revenues decreased by 4%.
Net loss, excluding special items, was $0.08 per share in the February quarter, compared to a loss of $0.16 per share in the corresponding period of 2024. On an unadjusted basis, net loss narrowed to $4.41 million or $0.11 per share in Q2 from $187.7 million or $4.67 per share in the prior-year quarter.
Revenues, on a reported basis, decreased 4% year-over-year to $72.0 million in the third quarter. The company expects fiscal 2025 sales to be in the range of $285 million to $288 million.
Commenting on the results, AngioDynamics’ CEO Jim Clemmer said, “Based on the quality of performance
we have seen through fiscal 2025, we are increasing our fiscal full-year guidance for all of our key metrics, including; total worldwide revenue, MedTech revenue growth, gross margin, adjusted EBITDA, and adjusted EPS.”
The post AngioDynamics (ANGO) Q3 2025 loss narrows; sales down 4% first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact legal@gsix.org
